Israel Englander’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Israel Englander’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,000	Closed	-$780K	–	7503
2021 Q2	$780K	Buy	10,000 +5,000	+100%	+$370K	﹤0.01%	4907
2021 Q1	$473K	Hold	5,000	–	–	﹤0.01%	4875
2020 Q4	$609K	Buy	+5,000	New	+$548K	﹤0.01%	4052

Israel Englander's TPTX Position: Q3 2022 in Review

Israel Englander sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 610,489 shares — an estimated $45.9M sold.

Israel Englander first reported a position in TPTX in Q3 2019 and held it in 11 quarters. The position peaked at $45.9M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Israel Englander reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Israel Englander sold 610,489 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $45.9M.
Israel Englander first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
Israel Englander's Turning Point Therapeutics, Inc. Common Stock position peaked at $45.9M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Millennium Management's 13F filing for Q3 2022, filed 14 Nov 2022.